← Leaderboards
Louis E Underwood
University Of North Carolina Chapel Hill
$5,889,688
Attributed
$5,889,688
Total exposure
9
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $18.2K · FY2005–08$20K$15K$10K$5K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$5,889,688 · 9
By mechanism
M01$5,889,688 · 9
Top collaborators
No co-investigators on record.
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- David Robert Clemmons$15,091,383
- Nicholas J Shaheen$48,001,410
- Gerry S Oxford$4,186,226
- Raymond G Booth$7,498,592
- Jeremy M Groll$1,981
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHuman Therapy EvaluationInsulinlike Growth FactorSomatotropinHormone TherapyChild Physical DevelopmentPostnatal Growth DisorderChild (0-11)Recombinant ProteinsDrug Screening /EvaluationHormone Regulation /Control MechanismSlow Release DrugBody HeightSkeletal Disorder ChemotherapyDihydroxyphenylalanineBlood ProteinsLongitudinal Human StudyPituitary DwarfismClonidineGrowth /DevelopmentHormone Sensitivity /ResistanceBiomarkerHypothalamic Pituitary Axis
Grant awards (47)
CLINICAL TRIAL: LONG-TERM RHIGF-I TREATMENT IN CHILDREN WITH SHORT STATURE DUE T$3,443
M01 · FY2008 · RR · contact PI
LONG-TERM RHIGF-I TREATMENT IN CHILDREN WITH SHORT STATURE DUE TO GHIS$11,255
M01 · FY2007 · RR · contact PI
LONG-TERM RHIGF-I TREATMENT IN CHILDREN WITH SHORT STATURE DUE TO GHIS$15,115
M01 · FY2006 · RR · contact PI
LONG-TERM RHIGF-I TREATMENT IN CHILDREN WITH SHORT STATURE DUE TO GHIS$18,221
M01 · FY2005 · RR
Long-Term rhIGF-I Treatment in Children with Short Stature Due to GHIS$17,548
M01 · FY2004 · RR
LONG TERM RHIGF I TREATMENT IN CHILDREN W/ SHORT STATURE DUE TO GHIS$190,747
M01 · FY2002 · RR
PROLEASE HGH IN CHILDREN W/ GROWTH FAILURE DUE TO GROWTH HORMONE DEFI$190,747
M01 · FY2002 · RR
GROWTH HORMONE IN PITUITARY DISORDERS$190,747
M01 · FY2002 · RR
RECOMBINANT HUMAN IGF-I IN CHILDREN WITH SHORT STATURE$190,747
M01 · FY2002 · RR
IGF GENERATION TEST AS MARKER OF GROWTH HORMONE SENSITIVITY$190,747
M01 · FY2002 · RR
PROLEASE HGH ADMINISTERED TO CHILDREN W/ GROWTH FAILURE$190,747
M01 · FY2002 · RR
PROLEASE HGH ADMINISTERED TO CHILDREN W/ GROWTH FAILURE$294,555
M01 · FY2001 · RR
LONG TERM RHIGF I TREATMENT IN CHILDREN W/ SHORT STATURE DUE TO GHIS$294,555
M01 · FY2001 · RR
PROLEASE HGH IN CHILDREN W/ GROWTH FAILURE DUE TO GROWTH HORMONE DEFI$294,555
M01 · FY2001 · RR
GROWTH HORMONE IN PITUITARY DISORDERS$294,555
M01 · FY2001 · RR
RECOMBINANT HUMAN IGF-I IN CHILDREN WITH SHORT STATURE$294,555
M01 · FY2001 · RR
IGF GENERATION TEST AS MARKER OF GROWTH HORMONE SENSITIVITY$294,555
M01 · FY2001 · RR
LONG TERM RHIGF I TREATMENT IN CHILDREN W/ SHORT STATURE DUE TO GHIS$190,747
M01 · FY2001 · RR
GROWTH HORMONE IN PITUITARY DISORDERS$190,747
M01 · FY2001 · RR
IGF GENERATION TEST AS MARKER OF GROWTH HORMONE SENSITIVITY$190,747
M01 · FY2001 · RR
PROLEASE HGH ADMINISTERED TO CHILDREN W/ GROWTH FAILURE$190,747
M01 · FY2001 · RR
RECOMBINANT HUMAN IGF-I IN CHILDREN WITH SHORT STATURE$190,747
M01 · FY2001 · RR
PROLEASE HGH IN CHILDREN W/ GROWTH FAILURE DUE TO GROWTH HORMONE DEFI$190,747
M01 · FY2001 · RR
RECOMBINANT HUMAN IGF-I IN CHILDREN WITH SHORT STATURE$294,555
M01 · FY2000 · RR
RECOMBINANT HUMAN IGF-I IN CHILDREN WITH SHORT STATURE$294,555
M01 · FY2000 · RR
RECOMBINANT HUMAN IGF-I IN CHILDREN WITH SHORT STATURE$294,555
M01 · FY2000 · RR
PROLEASE HGH ADMINISTERED TO CHILDREN W/ GROWTH FAILURE$294,555
M01 · FY2000 · RR
PROLEASE HGH ADMINISTERED TO CHILDREN W/ GROWTH FAILURE$294,555
M01 · FY2000 · RR
PROLEASE HGH ADMINISTERED TO CHILDREN W/ GROWTH FAILURE$294,555
M01 · FY2000 · RR
PROLEASE HGH ADMINISTERED TO CHILDREN W/ GROWTH FAILURE$241
M01 · FY2000 · RR
RECOMBINANT HUMAN IGF-I IN CHILDREN WITH SHORT STATURE$241
M01 · FY2000 · RR
PROLEASE HGH IN CHILDREN W/ GROWTH FAILURE DUE TO GROWTH HORMONE DEFI$0
M01 · FY2000 · RR
GROWTH HORMONE IN PITUITARY DISORDERS$0
M01 · FY2000 · RR
GROWTH HORMONE IN PITUITARY DISORDERS$0
M01 · FY2000 · RR
GROWTH HORMONE IN PITUITARY DISORDERS$0
M01 · FY2000 · RR
IGF AS MARKER OF GROWTH HORMONE SENSITIVITY$0
M01 · FY2000 · RR
IGF AS MARKER OF GROWTH HORMONE SENSITIVITY$0
M01 · FY2000 · RR
IGF AS MARKER OF GROWTH HORMONE SENSITIVITY$0
M01 · FY2000 · RR
IGF AS MARKER OF GROWTH HORMONE SENSITIVITY$0
M01 · FY2000 · RR
LONG TERM RHIGF I TREATMENT IN CHILDREN W/ SHORT STATURE DUE TO GHIS$0
M01 · FY2000 · RR
LONG TERM RHIGF I TREATMENT IN CHILDREN W/ SHORT STATURE DUE TO GHIS$0
M01 · FY2000 · RR
LONG TERM RHIGF I TREATMENT IN CHILDREN W/ SHORT STATURE DUE TO GHIS$0
M01 · FY2000 · RR
LONG TERM RHIGF I TREATMENT IN CHILDREN W/ SHORT STATURE DUE TO GHIS$0
M01 · FY2000 · RR
PROLEASE HGH IN CHILDREN W/ GROWTH FAILURE DUE TO GROWTH HORMONE DEFI$0
M01 · FY2000 · RR
PROLEASE HGH IN CHILDREN W/ GROWTH FAILURE DUE TO GROWTH HORMONE DEFI$0
M01 · FY2000 · RR
PROLEASE HGH IN CHILDREN W/ GROWTH FAILURE DUE TO GROWTH HORMONE DEFI$0
M01 · FY2000 · RR
GROWTH HORMONE IN PITUITARY DISORDERS$0
M01 · FY2000 · RR